Looking Back at PCPT: Looking Forward to New Paradigms in Prostate Cancer Screening and Prevention{A figure is presented}

Edith Canby-Hagino; Javier Hernandez; Timothy C. Brand; Ian Thompson

doi:10.1016/j.eururo.2006.09.002

Looking Back at PCPT: Looking Forward to New Paradigms in Prostate Cancer Screening and Prevention{A figure is presented}

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Objectives: Provide a critical summary of the latest interpretation of findings from the Prostate Cancer Prevention Trial (PCPT). Methods: Findings from PCPT and recently published post-hoc analyses are reviewed. Results: PCPT demonstrated that finasteride can reduce the prevalence of prostate cancer, permitted the first large-scale assessment of the performance characteristics of prostate-specific antigen for prostate cancer screening, and identified new-onset erectile dysfunction as an early predictor of cardiovascular events. Conclusions: PCPT has and will continue to yield valuable information regarding future strategies for prostate cancer prevention and detection, benign prostatic hyperplasia, and other matters of public health importance.

Original language	English (US)
Pages (from-to)	27-33
Number of pages	7
Journal	European Urology
Volume	51
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2006.09.002
State	Published - Jan 2007

Keywords

Finasteride
Prevention
Prostate cancer

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2006.09.002

Cite this

@article{d21ac92a44074648852540c607d8b497,

title = "Looking Back at PCPT: Looking Forward to New Paradigms in Prostate Cancer Screening and Prevention{A figure is presented}",

abstract = "Objectives: Provide a critical summary of the latest interpretation of findings from the Prostate Cancer Prevention Trial (PCPT). Methods: Findings from PCPT and recently published post-hoc analyses are reviewed. Results: PCPT demonstrated that finasteride can reduce the prevalence of prostate cancer, permitted the first large-scale assessment of the performance characteristics of prostate-specific antigen for prostate cancer screening, and identified new-onset erectile dysfunction as an early predictor of cardiovascular events. Conclusions: PCPT has and will continue to yield valuable information regarding future strategies for prostate cancer prevention and detection, benign prostatic hyperplasia, and other matters of public health importance.",

keywords = "Finasteride, Prevention, Prostate cancer",

author = "Edith Canby-Hagino and Javier Hernandez and Brand, {Timothy C.} and Ian Thompson",

year = "2007",

month = jan,

doi = "10.1016/j.eururo.2006.09.002",

language = "English (US)",

volume = "51",

pages = "27--33",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Looking Back at PCPT

T2 - Looking Forward to New Paradigms in Prostate Cancer Screening and Prevention{A figure is presented}

AU - Canby-Hagino, Edith

AU - Hernandez, Javier

AU - Brand, Timothy C.

AU - Thompson, Ian

PY - 2007/1

Y1 - 2007/1

N2 - Objectives: Provide a critical summary of the latest interpretation of findings from the Prostate Cancer Prevention Trial (PCPT). Methods: Findings from PCPT and recently published post-hoc analyses are reviewed. Results: PCPT demonstrated that finasteride can reduce the prevalence of prostate cancer, permitted the first large-scale assessment of the performance characteristics of prostate-specific antigen for prostate cancer screening, and identified new-onset erectile dysfunction as an early predictor of cardiovascular events. Conclusions: PCPT has and will continue to yield valuable information regarding future strategies for prostate cancer prevention and detection, benign prostatic hyperplasia, and other matters of public health importance.

AB - Objectives: Provide a critical summary of the latest interpretation of findings from the Prostate Cancer Prevention Trial (PCPT). Methods: Findings from PCPT and recently published post-hoc analyses are reviewed. Results: PCPT demonstrated that finasteride can reduce the prevalence of prostate cancer, permitted the first large-scale assessment of the performance characteristics of prostate-specific antigen for prostate cancer screening, and identified new-onset erectile dysfunction as an early predictor of cardiovascular events. Conclusions: PCPT has and will continue to yield valuable information regarding future strategies for prostate cancer prevention and detection, benign prostatic hyperplasia, and other matters of public health importance.

KW - Finasteride

KW - Prevention

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=33751422525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751422525&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2006.09.002

DO - 10.1016/j.eururo.2006.09.002

M3 - Review article

C2 - 17030406

AN - SCOPUS:33751422525

VL - 51

SP - 27

EP - 33

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -

Looking Back at PCPT: Looking Forward to New Paradigms in Prostate Cancer Screening and Prevention{A figure is presented}

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this